Please assess the completion status of the following clinical trial:

Trial Title: Experimental PfSPZ Vaccine in Adults Without Malaria

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA:~A volunteer must meet all of the following criteria to be included:~1. 18 to 45 years old adults.~2. Able and willing to participate for the duration of the study.~3. Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process.~4. Able and willing to complete the informed consent process.~5. Willing to donate blood for sample storage to be used for future research.~6. Willing to refrain from blood donation to blood banks for 3 years following P. falciparum challenge.~7. Agree not to travel to a malaria endemic region during the entire course of study participation.~8. Physical examination and laboratory results without clinically significant findings and a body mass index (BMI) less than or equal to 35 for Groups 1, 2, 3 and 4 or BMI less than or equal to 40 for Group 5.~   LABORATORY CRITERIA WITHIN 56 DAYS PRIOR TO ENROLLMENT:~9. Hemoglobin greater than or equal to 11.2 g/dL for women; greater than or equal to 13.0 g/dL for men.~10. Differential and platelet count either within institutional normal range or accompanied by site physician approval.~11. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than or equal to 1.25 times upper limit of normal (ULN) for Groups 1, 2, 3 and 4 or less than or equal to 1.75 ULN for Group 5.~12. Serum creatinine less than or equal to upper limit of normal.~13. Negative for HIV infection.~    LABORATORY CRITERION DOCUMENTED ANY TIME PRIOR TO ENROLLMENT:~14. Negative sickle cell screening test.~    FEMALE-SPECIFIC CRITERIA:~15. Negative beta-HCG pregnancy test (urine or serum) on day of enrollment for women presumed to be of childbearing potential.~16. A woman of childbearing potential must agree to use an effective means of birth control throughout the duration of study participation.~EXCLUSION CRITERIA:~A volunteer will be excluded if one or more of the following conditions apply:~1. Woman who is breast-feeding or planning to become pregnant during the time interval needed to complete the study.~2. Receipt of a malaria vaccine in a prior clinical trial.~3. Any history of malaria infection.~4. Evidence of increased cardiovascular disease risk; defined as \>10% five year risk by the non-laboratory method.~5. Screening EKG showing pathologic Q waves and significant ST-T wave changes; left ventricular hypertrophy; any non-sinus rhythm (except isolated premature atrial contractions); left bundle branch block; or advanced (secondary or tertiary) A-V heart block.~6. Current use of systemic immunosuppressant pharmacotherapy.~7. History of a splenectomy, sickle cell disease or sickle cell trait.~8. Plan for major surgery between enrollment and challenge.~9. Known allergy to any component of the vaccine formulation; history of anaphylactic response to mosquito-bites; or known allergy to chloroquine phosphate, atovaquone or proguanil.~10. Participation in any study involving another investigational vaccine or drug within 12 weeks prior to enrollment, or plan to participate in another investigational vaccine/drug research during the study.~11. Personal beliefs that prohibit the receiving of vaccine product containing human serum albumin within the diluent.~12. Use or planned use of any drug with anti-malarial activity that would coincide with study vaccination or challenge.~13. History of psoriasis or porphyria, which may be exacerbated after treatment with chloroquine.~14. Anticipated use of medications known to cause drug reactions with chloroquine or atovaquone-proguanil (Malarone) such as cimetidine, metoclopramide, antacids, and kaolin.~15. Psychiatric condition that precludes compliance with the protocol; past or present psychoses; disorder requiring lithium; or within five years prior to enrollment, history of a suicide plan or attempt.~16. Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer s ability to give informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete